{"id":59609,"date":"2024-06-27T16:04:36","date_gmt":"2024-06-27T14:04:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/optime-care-announces-enhanced-partnership-with-rigel-pharmaceuticals-for-gavreto-patients\/"},"modified":"2024-06-27T16:04:36","modified_gmt":"2024-06-27T14:04:36","slug":"optime-care-announces-enhanced-partnership-with-rigel-pharmaceuticals-for-gavreto-patients","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/optime-care-announces-enhanced-partnership-with-rigel-pharmaceuticals-for-gavreto-patients\/","title":{"rendered":"Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO\u00ae Patients"},"content":{"rendered":"
\n

ST. LOUIS–(BUSINESS WIRE)–Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth<\/a> Company, today announces a contractual partnership with Rigel Pharmaceuticals, Inc.<\/a>, effective July 1, 2024, bringing its comprehensive suite of services to support patients using GAVRETO\u00ae<\/a> (pralsetinib). GAVRETO\u00ae<\/a> is a targeted therapy that is taken by mouth once daily and is used to treat certain cancers caused by abnormal RET genes.<\/p>\n

<\/a>
<\/a><\/p>\n

\nOptime Care\u2019s offerings for life sciences manufacturers encompass pre-commercialization and market access expertise, exclusive distribution partnerships and national medication fulfillment. Seamless treatment is ensured through high-touch patient support and HUB services designed to enhance patient outcomes.<\/p>\n

\n\u201cOur dedicated team at Optime Care is excited to expand our long-standing partnership with Rigel Pharmaceuticals and support GAVRETO\u00ae patients,\u201d says Stephanie Wasilewski, PharmD, General Manager, Optime Care. \u201cOur comprehensive suite of services and deep commitment to personalized care optimize therapeutic outcomes throughout the treatment journey,\u201d says Stephanie Wasilewski, PharmD, General Manager, Optime Care.<\/p>\n

\nOptime Care specialists excel in communication, optimizing the patient journey through personalized clinical guidance and ongoing support for patients and their families. Professionals with deep understanding of complex, chronic disease have specialized experience that enhances patient access to essential therapies, streamlines care coordination, assists with insurance coverage to address financial needs and identifies financial assistance programs.<\/p>\n

\nRigel Pharmaceuticals, Inc. has an established relationship with Optime Care and based this selection for the management of GAVRETO\u00ae patients on the Company\u2019s expertise with specialized, complex diseases and comprehensive suite of integrated patient management and HUB services. This includes distribution, patient intake, prescription fulfillment, prior authorization support, custom clinical programs, reimbursement services and financial assistance.<\/p>\n

\n“Optime Care has consistently demonstrated exceptional expertise and commitment to patient care, making them an ideal partner for managing GAVRETO\u00ae patients,\u201d says Scott Yohe, VP of market access, Rigel Pharmaceuticals. “Their comprehensive services ensure that patients have access to the necessary resources and guidance, support that leads to improved therapeutic outcomes. We are excited to strengthen our collaboration and continue to make a positive impact on the lives of those affected by cancers caused by abnormal RET genes.”<\/p>\n

\nAbout Optime Care
\n
<\/b>Optime Care, Inc., an AscellaHealth Company, is a nationally recognized specialty pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize therapeutic opportunities for the treatment of orphan and rare disorders. The executive team has partnered in the launch and management of over 40 orphan products and programs while consistently implementing the best brand services for the community. Optime Care has dual-accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers. Visit www.ascellahealth.com<\/a><\/p>\n

\nAbout Rigel
\n
<\/b>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company’s marketed products and pipeline of potential products, visit www.rigel.com<\/a>.<\/p>\n

\nAbout GAVRETO\u00ae (pralsetinib)
\n
<\/b>GAVRETO\u00ae<\/b> is a prescription medicine used to treat certain cancers caused by abnormal rearranged during transfection (RET) genes in:<\/p>\n